DUBLIN–(BUSINESS WIRE)–The “Ribonucleotide Reductase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Ribonucleotide reductase inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Ribonucleotide reductase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Ribonucleotide reductase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Ribonucleotide reductase inhibitors.
Ribonucleotide reductase inhibitors Emerging Drugs Chapters
This segment of the Ribonucleotide reductase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ribonucleotide reductase inhibitors Emerging Drugs
G207: Treovir, LLC
G207 is engineered so that it selectively infects and kills tumor cells leaving healthy cells unharmed. Death of infected tumor cells releases G207 that spreads to infect additional tumor cells and to elicit a florid T-cell immune-related inflammatory response within the tumor. It is believed that the patient’s own immune response is a major basis for the anti-tumor efficacy of G207. G207 has been awarded Orphan Drug designation by the US FDA for treatment of medulloblastoma, Glioblastoma and primitive neuroectodermal brain tumor. The drug is currently being evaluated in Phase II stage of development for the treatment of pediatric high-grade glioma.
Ribonucleotide reductase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Ribonucleotide reductase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Ribonucleotide reductase inhibitors
There are approx. 3+ key companies which are developing the therapies for Ribonucleotide reductase inhibitors. The companies which have their Ribonucleotide reductase inhibitors drug candidates in the most advanced stage, i.e. phase II include Treovir, LLC.
Key Questions Answered
- How many companies are developing Ribonucleotide reductase inhibitors drugs?
- How many Ribonucleotide reductase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ribonucleotide reductase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ribonucleotide reductase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ribonucleotide reductase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Topics Covered:
Introduction
Executive Summary
Ribonucleotide reductase inhibitors: Overview
- Structure
- Function
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Mid Stage Products
- Comparative Analysis
G207: Treovir, LLC
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products
- Comparative Analysis
TAS1553: Astex Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Ribonucleotide reductase inhibitors Key Companies
Ribonucleotide reductase inhibitors Key Products
Ribonucleotide reductase inhibitors- Unmet Needs
Ribonucleotide reductase inhibitors- Market Drivers and Barriers
Ribonucleotide reductase inhibitors- Future Perspectives and Conclusion
Ribonucleotide reductase inhibitors Analyst Views
Ribonucleotide reductase inhibitors Key Companies
Appendix
Companies Mentioned
- Astex Pharmaceuticals
- Trethera
- Vion Pharmaceuticals
- Treovir, LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8mmepo
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900